Wilms tumor is the most common renal malignancy of childhood. To identify common variants that confer susceptibility to Wilms tumor, we conducted a genomewide association study in 757 individuals with Wilms tumor (cases) and 1,879 controls. We evaluated ten SNPs in regions significantly associated at P < 5 × 10 −5 in two independent replication series from the UK (769 cases and 2,814 controls) and the United States (719 cases and 1,037 controls). We identified clear significant associations at 2p24 (rs3755132, P = 1.03 × 10 −14 ; rs807624, P = 1.32 × 10 −14 ) and 11q14 (rs790356, P = 4.25 × 10 −15 ). Both regions contain genes that are plausibly related to Wilms tumorigenesis. We also identified candidate association signals at 5q14, 22q12 and Xp22.
l e t t e r s
Wilms tumor is the most common renal malignancy of childhood. To identify common variants that confer susceptibility to Wilms tumor, we conducted a genomewide association study in 757 individuals with Wilms tumor (cases) and 1,879 controls. We evaluated ten SNPs in regions significantly associated at P < 5 × 10 −5 in two independent replication series from the UK (769 cases and 2,814 controls) and the United States (719 cases and 1,037 controls). We identified clear significant associations at 2p24 (rs3755132, P = 1.03 × 10 −14 ; rs807624, P = 1.32 × 10 −14 ) and 11q14 (rs790356, P = 4.25 × 10 −15 ). Both regions contain genes that are plausibly related to Wilms tumorigenesis. We also identified candidate association signals at 5q14, 22q12 and Xp22.
Wilms tumor is a childhood embryonal kidney cancer that affects approximately 1 in 10,000 children in Western populations 1 . The median age of diagnosis is between 3 and 4 years, and both kidneys are affected in ~5% of children. Histologically, Wilms tumor mirrors the development of the normal kidney and classically contains the three cell types present in the embryonic kidney: blastema, epithelia and stroma 2 .
There is strong evidence of a genetic contribution to Wilms tumor. First, there is substantial variation in incidence that is attributable to ancestry rather than geographical location 1 . Second, approximately 2% of cases are familial 3 . Third, there are several predisposition syndromes associated with an increased risk of Wilms tumor, the most common of which are conditions that result from mutations in WT1 or epigenetic defects at 11p15 (ref. 3) . Fewer than 5% of Wilms tumor cases are attributable to known causes, and the underlying basis of most Wilms tumor cases is unknown 4, 5 .
We performed a genome-wide association study (GWAS) to identify genetic variants that confer susceptibility to Wilms tumor, using cases recruited through oncology clinics in North America. We compared the genotype frequencies in cases to those in data from North American controls obtained from the Database of Genotypes and Phenotypes (dbGaP) 6 . After quality control exclusions and removal of samples with non-European ancestry, we analyzed data on 599,255 SNPs in 757 cases and 1,879 controls. We compared genotype frequencies in cases and controls, primarily using the 1-degree-offreedom Cochran-Armitage trend test (Supplementary Fig. 1 ). There was evidence of only modest inflation of the test statistics (λ = 1.08), indicating that the extent to which population stratification confounded the results was limited (Supplementary Fig. 2) .
We next considered 20 SNPs in 9 regions of linkage disequilibrium (LD) that were significantly associated with Wilms tumor at P < 5 × 10 −5 . After eliminating SNPs that were strongly correlated with each other, we further evaluated these putative associations by genotyping ten SNPs at nine loci in two independent replication series. These series included 769 cases and 2,814 controls from the UK and 719 additional cases from North America. We did not have samples from US control individuals to directly genotype, so we analyzed the US l e t t e r s case genotypes against data from 1,037 additional controls obtained from dbGaP.
Two SNPs on chromosomes 2p24 and one SNP on chromosome 11q14 showed clear evidence of replication in each of the replication series separately (P = 4.1 × 10 −4 or better in the same direction as in the GWAS) and reached genome-wide significance levels over both stages combined of P = 1.03 × 10 −14 and 1.32 × 10 −14 at 2p24 and P = 4.25 × 10 −15 at 11q14 (Fig. 1 , Table 1 and Supplementary Tables 1 and 2) .
We also identified three low-frequency SNPs at 5q14, 22q12 and Xp22 for which associations achieved genome-wide significance with clear replication in the US series but with only weaker evidence of replication in the UK series ( Table 2 and Supplementary Tables 1  and 2 ). Accordingly, further replication studies are required to confirm these associations, as low-frequency variants in particular are susceptible to signal artifact when using different genotyping platforms for cases and controls.
We next used imputation to evaluate whether a more strongly associated variant was present at the loci, by estimating the genotype probabilities at additional SNPs using HapMap 3 and 1000 Genomes Project data as a framework. At four of the five loci, imputation identified more strongly associated variants than the original SNP ( Fig. 1 and  Supplementary Table 3) . In all regions, the imputed SNPs gave similar risk frequency profiles as the genotyped SNPs. Direct genotyping of these imputed SNPs in cases and controls would be of interest to confirm these associations. We also estimated the odds ratios associated with haplotypes of SNPs in each of the five genomic regions (Supplementary Table 4) . At each locus, either the association was present on more than one haplotype carrying the risk allele, suggesting that the association was unlikely to be driven by a single rarer, higher penetrance variant, or the association was only present on a single haplotype of similar frequency to the index SNP, thus affording no additional information. There was no evidence of departure from a log-additive model for any SNP, meaning that the odds ratios for rare homozygotes did not differ significantly from the square of the odds ratios for heterozygotes. There was also no evidence of statistical gene-gene interaction between loci; the combined effects of SNPs were consistent with multiplicative (log-additive) combination of effects.
We investigated whether the loci were associated with different risks in subgroups of Wilms tumor cases characterized by specific phenotypic features or risk factors, including sex, age at diagnosis, family history of Wilms tumor, whether the tumor was bilateral or unilateral, histology, disease stage and whether there was relapse after treatment (Supplementary Tables 5-7 ). rs790356 at 11q14 showed evidence of a stronger effect in females than males (P = 0.0017) and a trend in strength of association with increasing age at diagnosis (P = 0.0036). Genotyping of rs790356 in additional series would be of interest to further evaluate these associations. There was no significant difference in risk at any other SNP in any subgroup (Supplementary Tables 6 and 7).
The strongest evidence of association (P = 4.25 × 10 −15 ) was found at rs790356, which lies in a 68-kb LD block at 11q14.1 containing DLG2 (encoding discs, large homolog 2 (Drosophila)). The DLG2 protein is a member of the membrane-associated guanylate kinase protein family 7 . Dlg, the homolog of DLG2 in Drosophila melanogaster, functions with Scribbled and Lgl in the planar cell polarity pathway 8 . This pathway is essential for correct tissue morphogenesis during development, and its disruption has been implicated in oncogenesis 9 . Of note, the human homolog of Scribbled (encoded by SCRIB) is a recognized target of WT1, the Wilms tumor 1 gene product 5, 10 . npg l e t t e r s In mice, Scrib and Wt1 show coincident expression in the developing kidney. Moreover, in both mouse and human kidney cell lines, WT1 has been shown to bind the SCRIB promoter and activate SCRIB expression 10 . Thus, although the interactions of the DLG2 protein in humans have not been well characterized, it is plausible that susceptibility to Wilms tumor at the 11q14 locus is mediated through DLG2-and WT1-related pathways.
We identified two SNPs associated with Wilms tumor susceptibility in a 109-kb LD block at 2p24.3. The effects of rs3755132 and rs807624 were maintained when corrected for each other (odds ratio (OR) = 1.25; 95% confidence interval (CI) = 1.03-1.53 and OR = 1.21, 95% CI = 1.04-1.41, respectively; P = 0.01). Furthermore, the correlation between rs3755132 and rs807624 is weak (D′ = 1 and r 2 = 0.328 in HapMap 3 Utah residents of Northern and Western European ancestry (CEU) samples; D′ = 0.979 and r 2 = 0.328 in data from our GWAS controls). These data suggest that rs3755132 and rs807624 are independently associated with Wilms tumor. Because neither SNP alone can fully account for the association in this region, it is possible that a unique causal variant may exist that is in LD with rs3755132 and rs807624 and captures the effects of both of these SNPs. However, although imputation identified more strongly associated SNPs at this locus (Supplementary Table 3 ), none fully captured the associations of both rs3755132 and rs807624. rs3755132 is located 1.5 kb upstream of the promoter of DDX1 (encoding DEAD box helicase 1), whereas rs807624 is 11 kb 3′ of DDX1 and 52 kb 3′ of rs3755132. The DDX1 protein is involved in the initiation of translation and in RNA splicing and modification. It is also implicated in DNA double-strand break repair through its functions as an RNase and RNA-DNA helicase 11 . Notably, both SNPs are located within a region at 2p24 that shows somatic copy-number gain or amplification in many childhood cancers, most notably in neuroblastoma, but also occasionally in Wilms tumor 12, 13 . It is generally assumed that a neighboring gene in the amplicon, MYCN, is the primary target in promoting oncogenesis. Although it is possible that the association we identified is mediated through a long-range effect on MYCN, DDX1 seems to be the more likely target.
In summary, we have performed the first GWAS in Wilms tumor, identifying two definite and three candidate predisposition loci and providing insights into biological pathways that may be important in the genesis of this embryonal kidney cancer. The power to detect these loci was 21% for 2p24, 13% for 11q14, 4% for 22q12, 3% for Xp22 and <1% for 5q14. This strongly suggests that multiple loci of equivalent or weaker effect are likely to exist and may be identified through follow-up analysis of additional SNPs showing evidence of association in this study and/or through further GWAS. 
MeThodS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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Genotyping. For the GWAS, cases were genotyped using the Illumina HumanOmniExpress-12v1_A SNP array at the Broad Institute Genetic Analysis Platform. Each 96-well plate contained a HapMap CEU control. Samples were clustered and called from intensity data using BeadStudio version 3.1.3.0 with genotyping module version 3.2.32 (Illumina). Genotypes for the 1,879 controls used in the GWAS were generated using the Illumina Omni 1M array as part of the Center for Inherited Disease Research (CIDR): NGRC Parkinson's Disease Study.
For the replication studies, we used 5′ exonuclease assays (TaqMan, Applied Biosystems), following the manufacturer's protocols. We combined cases with controls on 384-well plates, each of which included at least two negative controls and 1-2% duplicates (intra-platform concordance was 98.96%). We performed cross-platform validation, genotyping by TaqMan all case samples that had been run on the Illumina array (cross-platform concordance was 99.11%). Genotypes for US replication samples were compared to those available from 1,037 US controls, which had been genotyped on the Illumina Omni 1M array as part of the High Density SNP Association Analysis of Melanoma study.
For rs2283873 at 22q12, the genotype frequencies were in Hardy-Weinberg equilibrium (HWE) in the GWAS, but there was some deviation from HWE in the replication analyses (Supplementary Table 2 ). We therefore undertook direct Sanger sequencing of rs2283873 to validate the TaqMan data and to confirm genotypes of 257 samples, including all those heterozygous or homozygous for the minor allele or that had failed TaqMan replication. There was full concordance between genotype calls determined by TaqMan and sequencing, thereby confirming the validity of the replication genotyping.
Inclusion criteria for analyses. We only included cases with a definite histological diagnosis of Wilms tumor. We excluded individuals with histological diagnoses of nephroblastomatosis, renal cell carcinoma, renal sarcoma, rhabdoid tumor and peripheral primitive neuroectodermal tumor (PNET). We restricted analyses to individuals that were called on >97% of successfully genotyped SNPs. We computed identity-by-state (IBS) probabilities for all pairs in order to identify cryptic duplicates and close relatives (IBS > 0.80).
For each pair identified, the sample with the highest genotype call rate was retained. We thus eliminated two cases, one from a pair of close relatives (IBS = 0.82) and one from a pair of duplicated samples (IBS > 0.99). Using a subset of 65,045 uncorrelated SNPs (r 2 < 0.1), we estimated the average IBS between all participants together with Phase 2 HapMap samples (90 CEU, 90 Ibadan from Yoruba, Nigeria (YRI), 44 Japanese from Tokyo (JPT) and 45 Han Chinese from Beijing (CHB)). Using multi-dimensional scaling, we identified and removed 42 cases with >15% non-European ancestry (27 with African ancestry and 15 with Asian ancestry). Furthermore, we excluded samples with abnormal heterozygosity (>5 s.d. from the mean heterozygosity; one case sample eliminated). Following these exclusions, 757 cases and 1,879 controls were available for the genome-wide analysis.
For the GWAS, we included the 696,780 SNPs that were successfully genotyped in cases and controls. We filtered out all SNPs in either cases or controls with (i) a minor allele frequency (MAF) of <1%, (ii) a call rate of <95% in cases or controls or (iii) a MAF of 1-5% with a call rate of <99%. We also excluded SNPs whose genotyped frequency departed from HWE at P < 1 × 10 −12 in cases or P < 0.00001 in controls (male samples were excluded for evaluation of HWE for SNPs on the X chromosome). We excluded synonymous (G>C and A>T) SNPs. Following these exclusions, we analyzed 599,255 SNPs genotyped in cases and controls. Cluster plots were inspected manually for all SNPs considered for replication.
For the replication, call rates of at least 97% per 384-well plate were required, and cluster plots were visually examined for each plate. Genotype distributions for each SNP were evaluated for deviation from HWE.
Statistical methods.
For the GWAS, we assessed associations between each SNP and disease primarily using the 1-degree-of-freedom Cochran-Armitage trend test; as a secondary measure of association, we performed the 1-degreeof-freedom allelic association test. Inflation in the χ 2 statistic was assessed using the genomic control approach. We derived an inflation factor (λ) by dividing the median of the lowest 90% of the 1-degree-of-freedom statistics by the 45% percentile of a 1-degree-of-freedom χ 2 distribution (0.357). Because λ was small, we chose to present P values uncorrected for λ, as this made little difference to the significance levels and preserved consistency with the replication analysis.
We selected 20 SNPs that showed association at a significance level of P < 5 × 10 −5 based on the 1-degree-of-freedom trend test in the GWAS for the replication phase. Where two or more SNPs were selected from the same region, we used multiple logistic regression to determine a minimal set of SNPs that showed evidence of association after adjustment for other SNPs.
We performed 1-degree-of-freedom tests of association for the GWAS and the US and UK replication analyses separately and then for the combined data stratified by stage (GWAS or replication) and study group (US or UK). For the principal association analysis, we have emphasized the OR estimates from the combined replication analysis (stratified by study) to minimize the effect of winner's curse. We assessed each SNP for dose response by comparing 1-degreeof-freedom and 2-degree-of-freedom logistic regression models, adjusting for stage, using a likelihood ratio test (P < 0.01), and examined the combined effects of multiple SNPs by evaluating the effect on the model of adding an interaction term, using a likelihood ratio test (P < 0.01) and adjusting for stage.
Modification of the per-allele ORs by covariate phenotype and/or risk factors was assessed using analysis of cases against all controls to generate strata-specific ORs and using case-only analysis to look for heterogeneity of effect (Supplementary Table 6 ). Tumors defined as stage 3 or 4 were categorized as advanced, and tumors defined as stage 1 or 2 were categorized as non-advanced; bilateral tumors, which are usually termed stage 5, were excluded from this analysis. Tumors with histology described as high-risk blastemal, high-risk diffuse anaplasia or unfavorable were categorized as high risk, and tumors with histology described as blastemal, cystic, intermediate, triphasic, favorable, intermediate-focal anaplasia or intermediate non-anaplastic were categorized as standard risk. Age of diagnosis was analyzed in three categories: <2 years, 2-4 years and >4 years, and the effect of age at diagnosis on SNP genotype in the cases was analyzed using ordered polytomous regression.
Imputation was performed using IMPUTE2 using data from HapMap 3 (~1.5 million SNPs, 1,184 individuals) and the 1000 Genomes Project low-coverage npg
